EUVIMEDEUVIMED entdecken
Crossref

Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users

John A Toms, Elizabeth O'Neill, Aaron L Wiegmann iD, Jubril Adepoju, Mamtha S Raj

Aesthetic Surgery Journal · 16.09.2024 · 44 (10) · 1072-1079

DOI: 10.1093/asj/sjae085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 15.04.2024. Verfasst von John A Toms und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Body Contouring, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of injectable glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic (Novo Nordisk, Plainsboro, NJ) and Wegovy (Novo Nordisk Inc.) has transformed weight loss in plastic surgery patients, often leading to excess skin and soft tissue amenable to body contouring procedures.

Objectives

The aim of this study was to examine the relationship between injectable GLP-1 receptor agonist use and the growing need for body contouring surgeries, focusing on trunk and extremity procedures.

Methods

A retrospective analysis of the PearlDiver database (PearlDiver, Inc., Colorado Springs, CO) was conducted, examining prescription data for Ozempic, Wegovy, and liraglutide, and correlating these with body contouring procedures across 30 US states from 2011 to 2022. Multimodal statistics were used to compare surgery rates and assess dosage and time interval patterns among GLP-1 receptor agonist users and nonusers.

Results

Significant correlations between GLP-1 receptor agonist use (881 Ozempic, 59 Wegovy, and 4655 liraglutide users) and increased body contouring surgeries were found. Ozempic showed weak correlations with brachioplasty (r = 0.23) and panniculectomy (r = 0.21), and Wegovy with breast procedures (r = 0.28), while liraglutide showed consistent correlations across surgeries. Time to surgery varied from 87 days (Wegovy) to 1018 days (liraglutide), with higher surgery rates among users (P < .01) and dose-related differences, especially in Ozempic and Wegovy users.

Conclusions

This study demonstrates a dose-dependent link between the use of GLP-1 receptor agonists and an increase in subsequent aesthetic body contouring surgeries, highlighting the need for surgeons to adapt to the merging of medicinal body transformation and aesthetic plastic surgery. Level of Evidence: 4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body ContouringLiraglutideGlucagon-Like Peptide-1 Receptor AgonistsHumansRetrospective StudiesUnited StatesInjectionsFemaleMaleWeight LossAdultMiddle AgedDatabases, FactualHypoglycemic Agents

Substanzen

LiraglutideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

ORCID-Profile: Aaron L Wiegmann

Zitieren

APA

Toms, J. A., O'Neill, E., Wiegmann, A. L., Adepoju, J., & Raj, M. S. (2024). Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users. Aesthetic Surgery Journal, 44(10), 1072-1079. https://doi.org/10.1093/asj/sjae085

Vancouver

Toms JA, O'Neill E, Wiegmann AL, Adepoju J, Raj MS. Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users. Aesthetic Surgery Journal. 2024;44(10):1072-1079. doi:10.1093/asj/sjae085

BibTeX
@article{Toms2024,
  author = {Toms, John A and O'Neill, Elizabeth and Wiegmann, Aaron L and Adepoju, Jubril and Raj, Mamtha S},
  title = {Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users},
  journal = {Aesthetic Surgery Journal},
  year = {2024},
  volume = {44},
  number = {10},
  pages = {1072--1079},
  doi = {10.1093/asj/sjae085}
}
Kostenlos starten →